News

Filter

Current filters:

ReproductiveVivus

European approval for Vivus' ED drug Spedra

27-06-2013

The European Commission yesterday (June 26) has granted marketing authorization for USA-based Vivus'…

avanafilEuropeMen's HealthPharmaceuticalRegulationReproductiveSpedraVivus

US FDA clears new ED drug Stendra

30-04-2012

The US Food and Drug Administration late Friday gave its approval for drug developer Vivus (Nasdaq: VVUS)…

avanafilMen's HealthNorth AmericaPharmaceuticalRegulationReproductiveStendraVivus

US NDA filings for Vivus’ ED drug avanafil and Corcept’s Corlux for Cushing’s

01-07-2011

California, USA-based Vivus (Nasdaq: VVUS) has submitted a New Drug Application has to the Food and Drug…

avanafilCorluxNorth AmericaPharmaceuticalRare diseasesRegulationReproductiveVivus

Vivus to sell MUSE assets to Sweden’s Meda in $23.5 million deal

05-10-2010

California, USA-based Vivus. (Nasdaq: VVUS) says that it has entered into an asset purchase agreement…

AlavenLicensingMedaMUSEPharmaceuticalQnexaReproductiveSwedenVivus

Positive Ph III results for VIVUS’ avanafil in diabetics with erectile dysfunction

08-06-2010

California, USA-based VIVUS announced positive results from the Phase III REVIVE-Diabetes (TA-302) study,…

avanafilDiabetesPharmaceuticalReproductiveResearchVivus

Vivus returns rights to develop Luramist to Acrux

01-04-2010

e USA’s Vivus has terminated the development and commercialization agreement with FemPharm, a wholly-owned…

AcruxLicensingLuramistPharmaceuticalReproductiveResearchVivus

Back to top